DSC Platform
More Than a Cell Source
Decinova’s DSC know-how extends beyond cell isolation. Built on the biological rationale and differentiation established for the platform, the DSC program incorporates deep, hands-on experience across the full translational pathway — from source tissue to clinical-ready product.
From Biology to Product
Platform Capabilities
Source & Isolation
Decidual tissue sourcing and cell-isolation strategy.
Expansion & Banking
Cell expansion, banking and scalable manufacturing concepts.
Characterization
Phenotypic and functional characterization relevant to product identity and biological activity.
Cryopreservation
Development of a cryopreserved product format supporting practical clinical use.
Preclinical Development
Biological, safety and toxicology experience supporting clinical translation.
Clinical Administration
Experience with dosing, handling, administration and clinical monitoring.
Regulatory Development
Experience generated through previous regulatory submissions and development programs across multiple jurisdictions.
DSC is distinguished from conventional stromal-cell sources by tissue origin, immunomodulatory phenotype and manufacturing process — see the full differentiation criteria on the DSC Therapeutics overview.